Interferon-gamma inhibits aldehyde dehydrogenase\textsuperscript{bright} cancer stem cells in the 4T1 mouse model of breast cancer

Xiufen Zhuang\textsuperscript{1}, Guilan Shi\textsuperscript{2,3}, Xiao Hu\textsuperscript{4}, Huiru Wang\textsuperscript{5}, Wen Sun\textsuperscript{1}, Yanhong Wu\textsuperscript{6}

\textsuperscript{1}Department of Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212000, China; \textsuperscript{2}Department of Immunology, Zibo Vocational Institute Health School, Zibo, Shandong 255000, China; \textsuperscript{3}Department of Medical Engineering, Morsani College of Medicine, Tampa, FL 33612, USA; \textsuperscript{4}Department of Oncology, Suqian First Hospital, Suqian, Jiangsu 223800, China; \textsuperscript{5}Department of Blood Transfusion, The First Affiliated Hospital of USTC, Hefei, Anhui 230001, China; \textsuperscript{6}Department of Medical Microbiology and Immunology, School of Basic Medical Sciences, Wannan Medical College, Wuhu, Anhui 241002, China.

Abstract

Background: Despite improvements in disease diagnosis, treatment, and prognosis, breast cancer is still a leading cause of cancer death for women. Compelling evidence suggests that targeting cancer stem cells (CSCs) have a crucial impact on overcoming the current shortcomings of chemotherapy and radiotherapy. In the present study, we aimed to study the effects of T cells and a critical anti-tumor cytokine, interferon-gamma (IFN-\(\gamma\)), on breast cancer stem cells.

Methods: BALB/c mice and BALB/c nude mice were subcutaneously injected with 4T1 tumor cells. Tumor growth and pulmonary metastasis were assessed. ALDEFLOUR\textsuperscript{TM} assays were performed to identify aldehyde dehydrogenase\textsuperscript{bright} (ALDH\textsuperscript{br}) tumor cells. ALDH\textsuperscript{br} cells as well as T cells from tumor-bearing BALB/c mice were analyzed using flow cytometry. The effects of CD\textsuperscript{8+} T cells on ALDH\textsuperscript{br} tumor cells were assessed in vitro and in vivo. The expression profiles of ALDH\textsuperscript{br} and ALDH\textsuperscript{dim} 4T1 tumor cells were determined. The levels of plasma IFN-\(\gamma\) were measured by enzyme-linked immunosorbent assay, and their associations with the percentages of ALDH\textsuperscript{br} tumor cells were evaluated. The effects of IFN-\(\gamma\) on ALDH expression and the malignancy of 4T1 tumor cells were analyzed in vitro.

Results: There were fewer metastatic nodules in tumor-bearing BALB/c mice than those in tumor-bearing BALB/c nude mice (25.40 vs. 54.67, \(P < 0.050\)). CD\textsuperscript{8+} T cells decreased the percentages of ALDH\textsuperscript{br} 4T1 tumor cells in vitro (control vs. effector to target ratio of 1:1, 10.15\% vs. 5.76\%, \(P < 0.050\)) and in vivo (control vs. CD\textsuperscript{8+} T cell depletion, 10.15\% vs. 21.75\%, \(P < 0.001\)). The functions of upregulated genes in ALDH\textsuperscript{br} 4T1 tumor cells were enriched in the pathway of response to IFN-\(\gamma\). The levels of plasma IFN-\(\gamma\) decreased gradually in tumor-bearing BALB/c mice, while the percentages of ALDH\textsuperscript{br} tumor cells in primary tumors increased. IFN-\(\gamma\) at a concentration of 26.68 ng/mL decreased the percentages of ALDH\textsuperscript{br} 4T1 tumor cells (22.88\% vs. 9.88\%, \(P < 0.050\)) and the protein levels of aldehyde dehydrogenase 1 family member A1 in 4T1 tumor cells (0.86 vs. 0.49, \(P < 0.050\)) and inhibited the abilities of sphere formation (sphere diameter \(< 200\mu\text{m}, 159.50 \text{vs.} 72.0; \geq 200\mu\text{m}, 127.0 \text{vs.} 59.0; \text{both} \(P < 0.050\)) and invasion (89.67 vs. 67.67, \(P < 0.001\)) of 4T1 tumor cells.

Conclusion: CD\textsuperscript{8+} T cells and IFN-\(\gamma\) decreased CSC numbers in a 4T1 mouse model of breast cancer. The application of IFN-\(\gamma\) may be a potential strategy for reducing CSCs in breast cancer.

Keywords: Cancer stem cells; Aldehyde dehydrogenase; Interferon-gamma; CD\textsuperscript{8+} T cells

Introduction

Breast cancer is still the most common malignancy and the second leading cause of cancer-related death in women.\textsuperscript{[1]} One reason that patients succumb to breast cancer is treatment resistance, which leads to metastasis and relapse.\textsuperscript{[2,3]} Several studies have suggested that breast cancer stem cells (BCSCs) mediate metastasis, are resistant to radiation and chemotherapy, and contribute to re-lapse.\textsuperscript{[4-6]} Cancer stem cells (CSCs) are a small population of cells in the tumor that have unique characteristics, such as self-renewal and the ability to generate heterogeneous lineages of cancer cells. Furthermore, CSCs exhibit characteristics of epithelial-to-mesenchymal transition, a known mechanism of metastasis.\textsuperscript{[5,7,8]} Therefore, BCSCs are considered to be the key population leading to resistance to radiotherapy and chemotherapy for breast cancer.\textsuperscript{[4,9]}
Researchers have found several potential markers that are suggested for the identification of BCSCs in clinical practice, such as CD44/CD24 and aldehyde dehydrogenase (ALDH) [5,10-12]. ALDH activity is a hallmark of BCSCs that is measurable by the ALDEFLUOR \(^{TM}\) (Stem Cell Technologies, Vancouver, BC, Canada) assay [13,14]. In studies using murine breast cancer models, increased ALDH activity has been commonly used to define CSCs [13]. ALDH is a member of the nicotinamide adenine dinucleotide-dependent enzyme family that catalyzes the oxidation of aldehydes to acids [16]. Aldehyde dehydrogenase 1 family member A1 (ALDH1A1) is an ALDH that can catalyze the oxidation of retinaldehyde to retinoic acid, which has been associated with the stemness of CSCs as well as normal tissue stem cells [13,17]. ALDH can prevent elevated levels of reactive oxygen species in drug-tolerant cancer cells [18] and protect cells from cytotoxic drugs [19]. Suppressing ALDH1A1 through specific small interfering RNA (siRNA) sensitizes colon cancer cells to chemothera py [20]. ALDH1A1-positive lung cancer cells displayed more resistance to gefitinib than ALDH1A1-negative lung cancer cells [16]. Inhibition of ALDH activity with the non-specific inhibitor diethylaminobenzaldehyde (DEAB) significantly suppressed the tumorsphere formation and lung metastasis abilities of breast cancer cells, including 4T1 cells. Silencing aldehyde dehydrogenase isoform 1 with a specific siRNA showed a similar inhibitory effect on tumorsphere formation [21]. Therefore, ALDH may be used as not only a marker for stem cells but also to regulate cellular functions related to self-renewal, expansion, differentiation, and resistance to drugs and radiation [18]. In our previous study, aldehyde dehydrogenase \(^{bright}\) (ALDH\(^{bright}\)) tumor cells were identified as CSCs for the 4T1 murine breast cancer cell line [22]. ALDH\(^{bright}\) could be used as a CSC marker in the 4T1 mouse model of breast cancer, and its increased activity was a major mechanism that led to treatment resistance in BCSCs [19,23-25].

The immunoenotyping theory consisting of immune elimination, equilibrium, and escape, is proposed to explain the dynamic interplay between the immune system and cancer cells. Immune cells, especially T lymphocytes, affect cancer cells, and even CSCs are associated with the prognosis of patients with breast cancer [26]. A major mechanism by which immune cells function is by releasing cytokines. Cytokines play an essential role in the development and propagation of a range of cell types, including cancer cells and CSCs [6,27]. Interferon-gamma (IFN-\(\gamma\)) is primarily secreted by activated T cells, natural killer cells, natural killer T cells, and gamma delta T (\(\gamma\)\(\delta\)T) cells, which play a pivotal role in systemic and local immunity and are involved in host anti-tumor immunity [28]. IFN-\(\gamma\) has been found to promote the apoptosis of CSCs in colon cancer [29], but it increases the percentages of CD133\(^+\) CSCs in hepatocellular carcinoma and does not promote the apoptosis of cell lines with high percentages of CD133 [30]. It has also been reported that IFN-\(\gamma\) increases the proliferation and colony formation abilities of CD34\(^+\) stem/progenitor cells from patients with chronic myeloid leukemia in \(v\)\(\text{itro}\) [31]. The effect of IFN-\(\gamma\) on CSCs seems to be cancer-context-dependent [32] and the effects of IFN-\(\gamma\) on CSCs in breast cancer is still unclear. IFN-\(\gamma\) could inhibit the growth and metastasis of 4T1 tumor cells through phagocytic cells in \(v\)\(i\)\(v\)\(o\) [33], however, the specific mechanisms are unknown. Whether it functions by inhibiting CSCs in 4T1 tumor cells remains to be identified. In addition, the effect of IFN-\(\gamma\) on ALDH expression in tumor cells has not been reported. Here, we found that IFN-\(\gamma\) inhibited ALDH expression in 4T1 tumor cells and decreased the percentages of ALDH\(^{+}\) 4T1 tumor cells, thus revealing a potential beneficial effect of IFN-\(\gamma\) on reducing CSCs in breast cancer.

Methods

Cell culture

4T1 tumor cells, a mammary gland tumor cell line with autonomous metastatic potency, were purchased from American type culture collection (ATCC; Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle medium: nutrient mixture F-12 (DMEM/F12) media (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (Zhejiang Tianhang Biotechnology, Huzhou, Zhejiang, China), 100 IU/mL penicillin, and 100 \(\mu\)g/mL streptomycin (Gibco, Grand Island, NY, USA) in a humidified atmosphere of 5% CO\(_2\) at 37°C.

Establishment of a subcutaneous 4T1 tumor model

Female BALB/c and BALB/c nude mice (5–6 weeks) were purchased from Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China) and maintained under specific pathogen-free conditions in the animal facility of Jiangsu University and Cancer Institute, Chinese Academy of Medical Sciences (Approval no.: SYXK[SI]2013-0036). All animal experiments were approved by the institutional review board of Jiangsu University and the Animal Care and Use Committee of the Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

A total of \(5 \times 10^4\) 4T1 tumor cells in 50 \(\mu\)L of phosphate-buffered saline (PBS) were injected subcutaneously into the right flank of a female BALB/c mouse or BALB/c nude mouse (five mice per group). Tumors were measured using digital calipers once every 3 to 4 days and volumes were calculated using the following formula: volume = 0.5 \(\times\) length \(\times\) width\(^2\). Three weeks later, the mice were sacrificed. Their lungs were dissected and fixed with Bouin fixation solution. Then, the lungs were weighed and the number of lung metastatic nodules was counted.

Flow cytometry assay of ALDH\(^{+}\) 4T1 tumor cells and tumor-infiltrating cells (TILs) in primary tumors

Single-cell suspensions of primary tumor tissues were obtained as previously described [32]. Briefly, four 4T1 tumor-bearing mice per group were sacrificed at the indicated time points, and the primary tumor masses were isolated, minced, and digested with type IV collagenase (1 mg/mL) (Sigma-Aldrich, St. Louis, MO, USA) and DNase I (300 U/mL) (Sigma-Aldrich) for approximately 1.5 h in a humidified atmosphere of 5% CO\(_2\) at 37°C. Cell suspensions were filtered through a 200-mesh screen and lysed with ammonium chloride solution (Stem Cell Technologies, Vancouver, BC, Canada) to exclude red
blood cells. The ALDEFLOUR™ assay for ALDH activity was performed according to the manufacturer’s instructions (ALDEFLOUR™ Kit, Stem Cell Technologies) as previously described. In brief, cells were incubated in ALDEFLOUR™ assay buffer containing activated ALDEFLOUR™ substrate at 37°C for 45 min. For negative controls, activated ALDEFLOUR™ substrates were added into cells and mixed, and DEAB was immediately added. Then, the cells were stained with allophycocyanin-conjugated anti-CD45 (APC-CD45) and its isotype antibody at 4°C in the dark for 30 min. For measuring TILs, a total of 10⁶ cells in 100 μL staining buffer were incubated with CD16/CD32 blocking antibodies at 4°C in the dark for 30 min. The ALDEFLOUR™ assay for ALDH activity in 4T1 tumor cells as mentioned above. ALDHbr 4T1 tumor cells and ALDHdim cells with high and low/negative ALDH activity were sorted using a FACSDiVa flow cytometer (BD Biosciences). Total RNA from both kinds of sorted cells were isolated using a CD8a+ T Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s instructions. 4T1 tumor cells were incubated with isolated CD8+ T cells at the indicated ratios. After 24-h incubation in a humidified atmosphere with 5% CO₂ at 37°C, culture supernatants were discarded and cells adhering to culture plates were washed twice with PBS, digested, and assessed using the ALDEFLOUR™ assay. ALDHbr 4T1 tumor cells were detected with a flow cytometer (BD LSRII, BD Biosciences). Gene expression microarray analysis of ALDHbr and ALDHdim 4T1 tumor cells

The ALDEFLOUR™ assay was used to detect ALDH activity in 4T1 tumor cells as mentioned above. ALDHbr and ALDHdim cells with high and low/negative ALDH activity were sorted using a FACSDiVa flow cytometer (BD Biosciences). Total RNA from both kinds of sorted cells was extracted using TRIzol reagent and analyzed using Affymetrix GeneChip mouse Transcriptome Array 2.0 (Shanghai Baygene Biotechnology Company Limited, Shanghai, China). Gene ontology (GO) annotation was used to determine the functions of differentially expressed genes between ALDHbr 4T1 tumor cells and ALDHdim 4T1 tumor cells. Prediction terms with a P value < 0.05 were selected and ranked by their P values. The −log₁₀(P value) yielding an enrichment score was used to rank the significant GO terms of differentially expressed genes.

Determination of ALDH1A1 messenger RNA (mRNA) levels by real-time polymerase chain reaction (PCR)

A total of 500,000 4T1 tumor cells were seeded into a 10-cm culture dish and cultured with or without JFN-γ (26.68 ng/mL, PeproTech, Rocky Hill, NJ, USA). mRNAs were isolated using the PrimeScript™ RT reagent Kit with genomic DNA (gDNA) Eraser, Takara, Dalian, China). mRNA levels were determined using TB Green™ Fast qPCR Mix (Takara) with a CFX96 Real-Time PCR System (Bio-Rad, Hercules, CA, USA). Primers for ALDH1A1 were purchased from Sangon Biotech Co. Ltd. (Shanghai, China) (F: TGTGAAGGGCTGCAAGACAGG R: TGTAGCCAGCAGCAAGCAGAT).
Determination of plasma IFN-γ using enzyme-linked immunosorbent assay (ELISA)

Plasma was collected from 4T1 tumor-bearing mice at the indicated time point. The concentrations of plasma IFN-γ were determined using a Mouse IFN-γ ELISA Kit (Dakewe Biotech Co., Ltd., Shenzhen, China) according to the manufacturer’s instructions.

Western blotting assay

A total of 500,000 4T1 tumor cells were seeded into a 10-cm culture dish and cultured with or without IFN-γ (26.68 ng/mL, PeproTech) for 24 h. The cells were harvested and lysed on ice with radioimmunoprecipitation assay lysis buffer (Solarbio, Beijing, China) containing a cocktail of proteinase inhibitors (Roche, Basel, Switzerland) for 30 min. Total proteins (30 μg/sample) were subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred onto a polyvinylidene difluoride membrane. Rabbit-anti-mouse ALDH1A1 (Abcam, Cambridge, MA, UK) and glyceraldehyde-3-phosphate dehydrogenase (CST, Danvers, MA, USA) were used at a dilution of 1:1000. After washing, horseradish peroxidase-coupled goat-anti-rabbit immunoglobulin G (IgG) antibodies (Abcam) were used at a dilution of 1:2000. Protein bands were visualized using an enhanced chemiluminescence detection system (Millipore, Danvers, MA, USA) and glyceraldehyde-3-phosphate dehydrogenase (CST, Danvers, MA, USA) were used at a dilution of 1:1000. After washing, 4',6-diamidino-2-phenylindole (Beyotime) was added for 5 min and washed and slides were mounted. Cells were observed under a fluorescence microscope (Leica, Wetzlar, Germany) at 400× magnification.

Immunocytochemistry (ICC)

A total of 60,000 4T1 tumor cells per well were seeded into a six-well plate in the presence or absence of IFN-γ (26.68 ng/mL, PeproTech) for 24 h. After washing with PBS, cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, and blocked with 1% bovine serum albumin (Solarbio). Then, treated cells were incubated with rabbit-anti-mouse ALDH1A1 (Abcam) at a dilution of 1:100 at 4°C overnight. After washing with PBS with Tween-20, cells were incubated with Alexa Fluor 488-conjugated goat-anti-rabbit immunoglobulin G (IgG) antibodies (Beyotime, Shanghai, China) at a dilution of 1:500 at room temperature for 1 h. After washing, 4',6-diamidino-2-phenylindole (Beyotime) was added for 5 min and washed and slides were mounted. Cells were observed under a fluorescence microscope (Leica, Wetzlar, Germany) at 400× magnification.

Sphere formation assay

A total of 15,000 4T1 tumor cells per well were seeded in an ultralow attachment six-well plate and cultured in plasma-free DMEM/F12 medium supplemented with 100 IU/mL penicillin, 100 μg/mL streptomycin (Gibco), epidermal growth factor (20 ng/mL, PeproTech), and basic fibroblast growth factor (20 ng/mL, PeproTech) with or without IFN-γ (26.68 ng/mL). One week later, the numbers of spheres were counted.

Migration and invasion assays

A total of 40,000 4T1 tumor cells per well were seeded into a 12-well Transwell insert with a pore size of 8 μm (CorStar, Corning, NY, USA) coated with or without 80 μL of Matrigel (Corning, Corning, NY, USA). DMEM/F12 supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 μg/mL streptomycin (Gibco) with or without IFN-γ (26.68 ng/mL, PeproTech) were added into the lower chamber of the well. After 24-h incubation, migrated or invaded cells on membranes were fixed, stained, and counted under a microscope at 200× magnification. Five fields on a membrane were viewed, cell numbers in each field were counted, and an average number was calculated.

Proliferation assay

A total of 3000 4T1 tumor cells per well were seeded into a 96-well plate and cultured with or without IFN-γ (26.68 ng/mL, PeproTech). After 24-h incubation, cell counting kit-8 reagents (Dojindo, Kumamoto, Japan) were added according to the manufacturer’s instructions and the optimal density value at 450 nm was measured with a microplate reader.

Statistical analyses

Statistical analyses were performed using SPSS version 10.0 (IBM SPSS Statistics, Armonk, NY, USA) or GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA). Data are presented as the means ± standard error. Independent Student’s t test or one-way analysis of variance followed by Dunnett multiple comparison test or Tukey multiple comparison test was performed to analyze differences between two groups. A P value of < 0.050 was considered statistically significant.

Results

Fewer pulmonary metastases were observed in BALB/c mice than those in BALB/c nude mice

BALB/c mice with a complete immune system and BALB/c nude mice without a thymus, and therefore, lacking CD8+ T cells are associated with decreased proportions of ALDHbr 4T1 tumor cells

CSCs are considered responsible for metastasis.[4] In our previous study, ALDHbr 4T1 tumor cells were identified as CSCs for the 4T1 murine breast cancer cell line.[22] In the present study, we also performed an ALDEFLUOR™ assay to identify ALDHbr 4T1 tumor cells [Figure 2A] and found that the proportions of ALDHbr 4T1 tumor cells in tumors from BALB/c mice increased with tumor growth (week 1 vs. week 2, 10.02% vs. 17.11%; week 2 vs. week 2.32, 0.050) [Figure 1A = 2.25, P < 0.050) [Figure 1C] in the BALB/c group than those in the BALB/c nude group. Although the primary tumor grew slowly in the BALB/c group, there was no significant difference between the BALB/c group and the BALB/c nude group in primary tumor volumes [Figure 1D].
vs. 20.22%; week 3 vs. week 4, 20.22% vs. 22.36%; \(F = 297.20, \text{all } P < 0.050\) [Figure 2B and Supplementary Figure 1A, http://links.lww.com/CM9/A589]. Moreover, in the spleens, the dominant CD4\(^+\) T cells and CD8\(^+\) T cells decreased gradually but the percentages of \(\gamma\delta\) T cells and two kinds of specific CD4\(^+\) T cells, that is, Tfh cells and Treg cells, were low and did not vary obviously [Figure 2C].

To determine whether CD4\(^+\) T cells and CD8\(^+\) T cells affect ALDH\(^{br}\) 4T1 tumor cells \textit{in vivo}, we depleted these two kinds of T cells in tumor-bearing BALB/c mice with antibodies. The depletion efficiencies for CD4\(^+\) T cells and CD8\(^+\) T cells in the spleen were >97% [Figure 2D and Supplementary Figure 1B, http://links.lww.com/CM9/A589]. With either CD4\(^+\) T cell or CD8\(^+\) T cell depletion, the percentages of ALDH\(^{br}\) 4T1 tumor cells in primary tumors were increased significantly compared with those in the control group without T cell depletion (control vs. CD4\(^+\) T cell depletion with anti-CD4 mAb, 10.15% vs. 19.13%; control vs. CD8\(^+\) T cell depletion with anti-CD8 mAb, 10.15% vs. 21.75%; \(F = 214.00, \text{all } P < 0.001\) [Figure 2E]. Therefore, both CD4\(^+\) and CD8\(^+\) T cells could inhibit the proportions of ALDH\(^{br}\) 4T1 tumor cells in tumors \textit{in vivo}.

Then, we detected CD4\(^+\) T cells and CD8\(^+\) T cells in TILs that may affect CSCs directly. We found that TILs contained both CD4\(^+\) T cells and CD8\(^+\) T cells, while CD8\(^+\) T cells accounted for a much higher proportion than CD4\(^+\) T cells, which may directly affect 4T1 tumor cells [Figure 2F and Supplementary Figure 2A, http://links.lww.com/CM9/A589]. Therefore, splenic CD8\(^+\) T cells from tumor-bearing BALB/c mice were isolated and cocultured with 4T1 tumor cells to investigate whether CD8\(^+\) T cells reduced the proportions of ALDH\(^{br}\) 4T1 tumor cells directly. We found that the percentages of ALDH\(^{br}\) 4T1 tumor cells decreased after coculturing 4T1 tumor cells with CD8\(^+\) T cells at different ratios (control vs. effector to target [E:T] ratio of 1:1, 10.15% vs. 5.76%; control vs. E:T ratio of 2:1, 10.15% vs. 4.64%; control vs. E:T ratio of 4:1, 10.15% vs. 6.32%; \(F = 10.46, \text{all } P < 0.050\) [Figure 2G and Supplementary Figure 2B, http://links.lww.com/CM9/A589], which indicates that CD8\(^+\) T cells may play a crucial role in inhibiting ALDH\(^{br}\) 4T1 tumor cells.

**ALDH expression in 4T1 tumor cells is associated with the response to IFN-\(\gamma\)**

On the other hand, to identify differences in gene expression between ALDH\(^{br}\) 4T1 tumor cells and 4T1 2.1, 10.15% vs. 5.76%; control vs. E:T ratio of 2:1, 10.15% vs. 4.64%; control vs. E:T ratio of 4:1, 10.15% vs. 6.32%; \(F = 10.46, \text{all } P < 0.050\) [Figure 2G and Supplementary Figure 2B, http://links.lww.com/CM9/A589], which indicates that CD8\(^+\) T cells may play a crucial role in inhibiting ALDH\(^{br}\) 4T1 tumor cells.
Figure 2: CD8+ T cells are associated with decreased proportions of ALDH^b 4T1 tumor cells. (A) Representative flow cytometry profiles of a negative control and a positive sample of ALDH^b 4T1 tumor cells. The proportion of ALDH^b 4T1 tumor cells was increased in the primary tumors of 4T1 tumor-bearing BALB/c mice. 4T1 tumor cells (5 x 10^4) were injected subcutaneously into BALB/c mice. (B) The primary tumors were isolated and digested at 1, 2, 3, and 4 weeks after tumor inoculation. At each week, four mice per group were determined. The ALDEFLOUR™ assay was performed and ALDH^b 4T1 tumor cells were determined by flow cytometry and gating of CD45^- cells. (C) Dynamic changes in T lymphocyte subsets in the spleens of 4T1 tumor-bearing BALB/c mice. Splenic CD4^+ T cells, CD8^+ T cells, γδT cells, Tfh cells, and Tregs were analyzed by flow cytometry at 1, 2, and 3 weeks after tumor inoculation, gating of living cells. At each week, four mice per group were analyzed. (D) Depletion efficiencies for CD4^+ T cells and CD8^+ T cells in vivo. Anti-CD4 monoclonal antibodies or anti-CD8 monoclonal antibodies were injected via the tail vein on day -5 and day -1 before 4T1 tumor inoculation and thereafter once every 4 to 5 days. Two weeks after tumor inoculation, mice were sacrificed, and the percentages of splenic CD4^+ T cells and CD8^+ T cells were analyzed by flow cytometry, gating living cells. Four mice per group were detected. (E) The percentages of ALDH^b tumor cells increased in tumors of 4T1 tumor-bearing BALB/c mice after CD4^+ T cell and CD8^+ T cell depletion. The primary 4T1 tumors were isolated and digested. The ALDEFLOUR™ assay was performed, and ALDH^b 4T1 tumor cells in tumors were determined by flow cytometry and gating of CD45^- cells. Four mice per group were assessed. (F) The percentage of CD4^+ T cells and CD8^+ T cells in tumors from 4T1 tumor-bearing BALB/c mice. The primary tumors were isolated and digested 2 weeks after tumor inoculation, and CD4^+ TILs and CD8^+ TILs were analyzed by flow cytometry, gating CD4^+ and CD8^+ cells. Four mice per group were analyzed. (G) The percentages of ALDH^b 4T1 tumor cells after coculturing of 4T1 tumor cells with splenic CD8^+ T cells at effector-to-target ratios of 1:1, 2:1, and 4:1. Twenty-four hours later, the ALDEFLOUR™ assay was performed and ALDH^b 4T1 tumor cells were determined by flow cytometry and gating of CD45^- cells. Data are presented as the mean ± SE. P < 0.050; †P < 0.010; ‡P < 0.001. ALDH^b: Aldehyde dehydrogenasebright; TILs: Tumor-infiltrating cells.
tumor cells expressing low to negative ALDH (ALDH\textsuperscript{dim}), we sorted ALDH\textsuperscript{br} and ALDH\textsuperscript{dim} 4T1 tumor cells by flow cytometry and determined their expression profiles using a gene chip assay. Significantly dysregulated genes in ALDH\textsuperscript{br} 4T1 tumor cells were identified, and GO annotation was used to determine which functions these significantly dysregulated genes were enriched. The top ten enriched GO terms for dysregulated genes in ALDH\textsuperscript{br} 4T1 tumor cells were ranked by enrichment score. The top ten enriched GO terms for dysregulated genes in ALDH\textsuperscript{br} 4T1 tumor cells were ranked by enrichment score. The top ten enriched GO terms for dysregulated genes in ALDH\textsuperscript{br} 4T1 tumor cells were ranked by enrichment score. The top ten enriched GO terms for dysregulated genes in ALDH\textsuperscript{br} 4T1 tumor cells were ranked by enrichment score. The top ten enriched GO terms for dysregulated genes in ALDH\textsuperscript{br} 4T1 tumor cells were ranked by enrichment score.

**Figure 3:** ALDH expression in 4T1 tumor cells is associated with the response to IFN-\( \gamma \). (A) The top ten GO terms for upregulated and downregulated genes in ALDH\textsuperscript{br} 4T1 tumor cells. ALDH\textsuperscript{br} and ALDH\textsuperscript{dim} 4T1 tumor cells were sorted with flow cytometry and expression profiles were detected using an Affymetrix GeneChip mouse transcriptome array. GO annotations were used to determine the functions of differentially expressed genes in ALDH\textsuperscript{br} 4T1 tumor cells compared with ALDH\textsuperscript{dim} 4T1 tumor cells. Prediction terms with a \( P \) value < 0.05 were selected and ranked by their \( P \) values. The \(-\log_{10}(P \text{ value})\) yields an enrichment score representing the significance of GO term enrichment among differentially expressed genes. The top ten enriched GO terms for dysregulated genes in ALDH\textsuperscript{br} 4T1 tumor cells were ranked by enrichment score. (B) Relative expression of ALDH1A1 (a member of the ALDH family) in 4T1 tumor cells treated with or without IFN-\( \gamma \) (26.68 ng/mL) for 24 h. The mRNA levels of ALDH were determined by real-time PCR. (C) The levels of plasma IFN-\( \gamma \) are associated with the proportions of ALDH\textsuperscript{br} 4T1 tumor cells in BALB/c mice. The plasma IFN-\( \gamma \) levels of 4T1 tumor-bearing mice were determined by ELISA at 1, 2, and 3 weeks after tumor inoculation. Data are presented as the mean \( \pm \) SE. \( P < 0.010 \). ALDH\textsuperscript{br}: Aldehyde dehydrogenase\textsuperscript{bright}; ELISA: Enzyme-linked immunosorbent assay; GO: Gene ontology; IFN-\( \gamma \): Interferon-\( \gamma \).

**IFN-\( \gamma \) inhibited ALDH protein expression in 4T1 tumor cells**

To further identify whether IFN-\( \gamma \) affected ALDH\textsuperscript{br} 4T1 tumor cells directly, we treated 4T1 tumor cells with IFN-\( \gamma \) at different concentrations \textit{in vitro}. We found a dose-dependent inhibitory effect of IFN-\( \gamma \) on the percentages of
ALDH<sup>br</sup> 4T1 tumor cells [Figure 4A and Supplementary Figure 2C, http://links.lww.com/CM9/A589]. Compared with a concentration of 6.67, 26.68 ng/mL of IFN-γ significantly decreased the percentages of ALDH<sup>br</sup> 4T1 tumor cells (22.88% vs. 9.88%, \( t = 2.25, P < 0.050 \)). Then, we investigated ALDH expression in 4T1 tumor cells treated with IFN-γ (26.68 ng/mL). The results from ICC [Figure 4B] and Western blotting [Figure 4C] showed that the protein levels of ALDH1A1 in 4T1 tumor cells were significantly decreased after IFN-γ (26.68 ng/mL) treatment (0.86 vs. 0.49, \( t = 2.61, P < 0.050 \)) [Figure 4D].

**IFN-γ** attenuated sphere formation and the invasion of 4T1 tumor cells

To investigate whether IFN-γ attenuated the malignancy of 4T1 tumor cells directly, we measured the sphere formation, migration, invasion, and proliferation of 4T1 tumor cells treated with or without IFN-γ. We found that the number of formed spheres was reduced significantly in 4T1 tumor cells cultured in the presence of IFN-γ (sphere diameter <200 μm, control vs. IFN-γ treatment, 159.30 vs. 72.0, \( t = 10.23; \geq 200 \) μm, control vs. IFN-γ treatment, 127.0 vs. 59.0, \( t = 7.95; \) both \( P < 0.050 \) ) [Figure 5A and 5B]. The invasion of 4T1 tumor cells was also inhibited significantly after IFN-γ treatment (89.67 vs. 67.67, \( t = 10.31, P < 0.001 \) ) [Figure 5C and 5D]. IFN-γ also inhibited the migration of 4T1 tumor cells to some degree, although there was no significant difference (\( P = 0.063 \)) [Figure 5C and 5D]. No significant difference in cellular proliferation was observed between 4T1 tumor cells treated with and without IFN-γ in vitro [Figure 5E], which may also suggest that decreased ALDH expression in 4T1 tumor cells [Figure 4B–D] is due to the inhibition of ALDH expression in individual cells instead of cytotoxicity of IFN-γ to ALDH<sup>br</sup> 4T1 tumor cells. The decreased sphere formation and invasion after IFN-γ treatment indicates that IFN-γ attenuated the cancer stem-like character of 4T1 tumor cells, which may play a role in inhibiting tumor metastasis.

**Discussions**

In the present study, we observed fewer pulmonary metastatic nodules in tumor-bearing BALB/c mice than those in tumor-bearing BALB/c nude mice. CD8<sup>+</sup> T cells decreased the percentages of ALDH<sup>br</sup> 4T1 tumor cells in vitro and in vivo. Upregulated genes associated with the response to IFN-γ were enriched in ALDH<sup>br</sup> 4T1 tumor cells. The plasma IFN-γ levels were decreased as the percentage of ALDH<sup>br</sup> tumor cells increased in tumor-bearing BALB/c mice. IFN-γ treatment decreased the protein levels of ALDH1A1 in 4T1 tumor cells and inhibited the sphere formation and invasion abilities of 4T1 tumor cells.

The results of fewer pulmonary metastatic nodules in BALB/c mice than those in BALB/c nude mice confirmed [Figure 1A–C] that T cells play a vital role in inhibiting...
tumor invasion, which was consistent with the inhibitory effect of IFN-γ, a critical anti-tumor effector of T cells, on tumor invasion in vitro [Figure 5C and 5D]. The decreased percentages of ALDHbr 4T1 tumor cells after coculturing CD8+ T cells with 4T1 tumor cells [Figure 2G] were also consistent with the decreased percentages of ALDHbr 4T1 tumor cells and ALDH expression in 4T1 tumor cells treated with IFN-γ [Figure 4]. Pulaski et al[33] showed that IFN-γ may inhibit metastasis of 4T1 tumor cells in vivo via host-derived phagocytic cells. Therefore, both IFN-γ and CD8+ T cells could attenuate the stemness of 4T1 tumor cells to some degree. After depletion of either CD4+ T cell type, the proportions of ALDHbr cells also increased significantly. CD4+ T cells are critical for the priming of tumor-specific CD8+ T cells and the secondary expansion and memory of CD8+ T cells.33,36 In TILs of the 4T1 tumor model, CD4+ T cells changed their dominant subsets from Th1 to Treg and Th17 during tumor growth.37 In the 4T1 tumor model, depletion of Tregs with anti-CD25 antibodies induced tumor regression, and the number of infiltrated CD8+ T cells increased after Treg depletion. However, the further depletion of CD4+ T cells with anti-CD4 antibodies after Treg depletion did not increase the number of infiltrated CD8+ T cells, and the level of IFN-γ secreted by infiltrated CD8+ T cells was decreased, which ascribes a primary role of the CD4 Th cells in the process of tumor regression.38 Without CD4+ effector T cells, CD8+ T cell activity and the production of IFN-γ are impaired, which may confer increased proportions of ALDHbr cells in vivo.

Regarding the growth of primary tumors in BALB/c mice and BALB/c nude mice, no significant difference was observed between the two groups [Figure 1D]. This result was similar to that of the proliferation assay in vitro, in which IFN-γ did not show significant inhibitory effects on cell proliferation [Figure 5E]. Different effects of IFN-γ on cancer cells may be explained by the varied levels of IFN-γ receptors. Kmieciak et al[39] showed that tumor cells that express high levels of IFN-γ R0 were eliminated by CD8+ T cells, whereas those with low levels did not die and remained dormant in the presence of IFN-γ-producing
CD8+ T cells until losing the neu antigen, whereupon the tumor relapsed. 4T1 tumor cells express the IFN-γ receptor and the expression levels were not varied by IFN-γ treatment,[40] which may partially explain the lack of an inhibitory effect of IFN-γ on the proliferation of 4T1 tumor cells in vitro. The lack of a difference in tumor growth between BALB/c mice and BALB/c nude mice may also be due to the effects of various suppressive immune factors in vivo, such as myeloid-derived suppressive cells, which are IFN-γ-promoted, and suppress the anti-tumor effector T cell response,[41] which were not analyzed in the present study.

CSCs are relatively resistant to conventional chemotherapeutic regimens and radiation and are very likely to be the origin of cancer metastasis, relapse, and progression.[42-45] Specifically, the expression of the ALDH1A1 isoform correlates with a higher tumor grade and tumor metastasis.[19,46] In this study, we found that CD8+ T cells and IFN-γ decreased the percentages of CSCs in breast cancer, that is, ALDHbr 4T1 tumor cells. In addition, IFN-γ directly inhibited ALDH1A1 expression in 4T1 tumor cells, which may contribute to attenuated sphere-forming ability.[47] Thus, IFN-γ can be combined with chemotherapy and radiotherapy, which may enrich CSCs in cancer treatment. In addition, blocking immunosuppressive factors may be necessary if IFN-γ is used in vivo.

The limitations of the present study should be noted. The percentage changes in ALDHbr 4T1 tumor cells in mice after IFN-γ depletion could be assessed to confirm the effects of IFN-γ on ALDHbr 4T1 tumor cells in vivo. IFN-γ blockade in the coculture of CD8+ T cells with 4T1 tumor cells will suggest whether CD8+ T cells decrease the percentages of ALDHbr 4T1 tumor cells through IFN-γ. In the future, whether IFN-γ is secreted by CD8+ T cells and subsequently favors the downregulation of ALDH expression in 4T1 tumor cells needs to be determined. The mechanisms behind the effects of IFN-γ on 4T1 stem cells need further study.

To conclude, we found that IFN-γ may play a crucial role in inhibiting BCSCs. Combining IFN-γ therapy with chemotherapy or radiotherapy and strategies for blocking immunosuppressive factors may improve the prognosis of breast cancer patients.

Acknowledgements

The authors are grateful to Mr. David A Snouffer for his helpful and critical comments during the preparation of this manuscript and sincerely thank Prof. Shuren Zhang for his suggestions on the organization and discussions of this manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No. 81402442 and No. 81903637) and the Fundamental Research Funds for the Central Universities (WK9110000027).

Conflicts of interest

None.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34. doi: 10.3322/caac.21551.
2. Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int 2018;2018:5416923. doi: 10.1155/2018/5416923.
3. Buan L, Xu FR, Jiang ZF. Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer. Chin Med J 2020;133:2338–2345. doi: 10.1097/CM9.000000000000923.
4. De Angelis ML, Francescangeli F, Zeuner A. Breast cancer stem cells as drivers of tumor chemoresistance, dormancy and relapse: new challenges and therapeutic opportunities. Cancers (Basel) 2019;11:13569. doi: 10.3390/cancers111013569.
5. Liu S, Cong Y, Wang D, Su L, Liu Y, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep 2014;2:78–91. doi: 10.1016/j.stemcr.2013.11.009.
6. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytoke networks, and the tumor microenvironment. J Clin Invest 2011;121:3804–3809. doi: 10.1172/jci75099.
7. Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, et al. EMT and tumor metastasis. Clin Transl Med 2015;4:46. doi: 10.1186/s41691-016-0048-3.
8. Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell 2019;49:361–374. doi: 10.1016/j.devcel.2019.04.010.
9. Nunes T, Hamdan D, Leboeuf C, El Bouchtaou M, Gapihan G, Nguyen TT, et al. Targeting cancer stem cells to overcome chemoresistance. Int J Mol Sci 2018;19:4036. doi: 10.3390/ijms19124036.
10. Shima H, Yamada A, Ishikawa T, Endo I. Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy? Gland Surg 2017;6:82–88. doi: 10.21037/gs.2016.08.03.
11. Horimoto Y, Arakawa A, Sasahara N, Tanabe M, Sai S, Himuro T, et al. Combination of cancer stem cell markers CD44 and CD24 is superior to ALDH1 as a prognostic indicator in breast cancer patients with distant metastases. PLoS One 2016;11:e0163253. doi: 10.1371/journal.pone.0163253.
12. Reaz N, Idrens R, Habib S, Azam I, Lalani EM. Expression of androgen receptor and cancer stem cell markers (CD44(+)/CD24(-) and ALDH1(+)): mechanistic implications in invasive breast cancer. Transl Oncol 2018;11:920–929. doi: 10.1016/j.tranon.2018.05.002.
13. Marcato P, Dean CA, Giacomantonio CA, Lee PWK. Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011;10:1378–1384. doi: 10.4161/cc.10.9.15486.
14. Vassalli G. Aldehyde dehydrogenases: not just markers, but functional regulators of stem cells. Stem Cells Int 2019;2019:3904645. doi: 10.1155/2019/3904645.
15. Sultan M, Vidovic D, Faine AS, Huynh TT, Coyle KM, Thomas ML, et al. Epigenetic silencing of TAP1 in Aldeburh(+) breast cancer stem cells contributes to their enhanced immune evasion. Stem Cells 2018;36:641–654. doi: 10.1002/stem.2780.
16. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH, et al. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett 2013;328:144–151. doi: 10.1016/j.canlet.2012.08.021.
17. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isofrom ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011;29:32–45. doi: 10.1002/stem.563.
18. Raha D, Wilson TR, Peng J, Peterson D, Yue P, Evangelista M, et al. The cancer stem cell marker aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget 2016;7:11018–11032. doi: 10.18632/oncotarget.6920.
33. Pulaski BA, Smyth MJ, Ostrander-Rosenberg S. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res 2002;62:4406–4412.

34. Laky K, Krasuski AM. In vivo depletion of T lymphocytes. Curr Protoc Immunol 2016;11:341–419. doi: 10.1002/0471142735.im0401133.

35. Janssen EM, Lemmens EE, Wolf T, Christen U, von Herrath MG, Scholzenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003;421:852–856. doi: 10.1038/nature01441.

36. Pardoll DM, Tolvanen SL. The role of CD8+ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588–594. doi: 10.1016/S0952-7915(98)80228-8.

37. Huang Y, Ma C, Zhang Q, Ye J, Wang F, Zhang Y, et al. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. Oncotarget 2015;6:17462–17478. doi: 10.18632/oncotarget.3958.

38. Chaput N, Darrasse-Jeze G, Bergot AS, Cordier C, Ngo-Abdalla S, Klatzmann D, et al. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol 2007;179:4969–4978. doi: 10.4049/jimmunol.179.8.4969.

39. Kmieciak M, Payne KK, Wang XY, Manjili MH. IFN-gamma Ralpha 1 is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse. PLoS One 2013;8:e82544. doi: 10.1371/journal.pone.0082544.

40. duPre SA, Redelman D, Hunter KW Jr. Microenvironment of the murine mammary carcinoma 4T1: endogenous IFN-gamma affects tumor phenotype, growth, and metastasis. Exp Mol Pathol 2008;85:174–188. doi: 10.1016/j.yexmp.2008.05.002.

41. Guo Q, Lv Z, Fu Q, Jiang C, Liu Y, Lai L, et al. IFN-gamma producing T cells contribute to the increase of myeloid derived suppressor cells in tumor-bearing mice after cyclophosphamide treatment. Int Immunopharmacol 2012;12:425–432. doi: 10.1016/j.intimp.2011.12.016.

42. Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci 2018;25:20. doi: 10.1186/s12929-018-0426-4.

43. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008;68:3243–3250. doi: 10.1158/0008-5472.can-07-5480.

44. Battle E, Clevers H. Cancer stem cells revisited. Nat Med 2017;23:1124–1134. doi: 10.1038/nm.4409.

45. Nandi S, Ulasov IV, Tyler MA, Sugihara AQ, Molinero L, Han Y, et al. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res 2008;68:5778–5784. doi: 10.1158/0008-5472.can-07-6441.

46. Griesemer C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555–567. doi: 10.1016/j.stem.2007.08.014.

How to cite this article: Zhuang X, Shi G, Hu X, Wang H, Sun W, Wu Y. Interferon-gamma inhibits aldehyde dehydrogenases (ALDH) cancer stem cells in the 4T1 mouse model of breast cancer. Chin Med J 2022;135:194–204. doi: 10.1097/CMA.0000000000001558.